-
Another innovative drug has been returned by Bristol Myers Squibb, with consecutive returns possibly related to strategic adjustments
Recently, at the 2024 Annual Meeting of the European Society of Medical Oncology (ESMO), Immatics announced the latest clinical data of IMA401, a TCR (T-cell binding receptor) bispecific molecular pr ...